We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-4.13%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$706M
AUM Growth
-$264M
Cap. Flow
-$179M
Cap. Flow %
-25.29%
Top 10 Hldgs %
84.23%
Holding
36
New
6
Increased
4
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$34.5M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$18.4M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$17.4M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$8.51M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.47M

Top Sells

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$70M
2
NKTR icon
Nektar Therapeutics
NKTR
+$63M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$39.6M
4
TGTX icon
TG Therapeutics
TGTX
+$21.3M
5
ARDX icon
Ardelyx
ARDX
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.12B
$185M 26.26%
7,088,651
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.5B
$109M 15.51%
5,409,990
+1,728,499
+47% +$34.5M
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
$90.2M 12.79%
1,890,796
+158,522
+9% +$8.47M
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$56.3M 7.98%
13,633,220
+1,600,000
+13% +$8.51M
NGNE icon
5
Neurogene
NGNE
$672M
$36.2M 5.13%
109,599
– –
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
$29.8M 4.22%
2,451,237
-204,929
-8% -$2.25M
ARDX icon
7
Ardelyx
ARDX
$1.24B
$27.5M 3.89%
1,935,305
-1,330,740
-41% -$18.9M
RARX
8
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$20.5M 2.91%
+1,351,808
New +$18.4M
FOMX
9
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$20.2M 2.86%
1,820,138
– –
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.42B
$18.9M 2.68%
2,989,795
– –
MYOV
11
DELISTED
Myovant Sciences Ltd.
MYOV
$18.7M 2.64%
+1,500,000
New +$17.4M
PTGX icon
12
Protagonist Therapeutics
PTGX
$8.55B
$14.6M 2.07%
692,563
-61,848
-8% -$1.38M
AIMT
13
DELISTED
Aimmune Therapeutics
AIMT
$13.9M 1.96%
677,663
-615,277
-48% -$12.6M
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.73M 1.38%
532,426
-175,000
-25% -$3.02M
ONC
15
BeOne Medicines Ltd
ONC
$33.9B
$7.29M 1.03%
240,000
+70,000
+41% +$2.2M
DRNA
16
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$6.99M 0.99%
2,428,571
– –
ABEO icon
17
Abeona Therapeutics
ABEO
$355M
$5.54M 0.79%
+45,714
New +$7.16M
SBBP
18
DELISTED
Strongbridge Biopharma plc.
SBBP
$5.47M 0.78%
2,279,099
-222,568
-9% -$907K
TGTX icon
19
TG Therapeutics
TGTX
$8.19B
$4.67M 0.66%
1,004,314
-3,626,800
-78% -$21.3M
TENX icon
20
Tenax Therapeutics
TENX
$393M
$4.66M 0.66%
75
– –
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$4.18M 0.59%
+591,070
New +$4.36M
EIGR
22
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.13M 0.58%
11,807
– –
DMTX
23
DELISTED
Dimension Therapeutics, Inc
DMTX
$4.04M 0.57%
928,199
-619,834
-40% -$3.3M
ACGN
24
DELISTED
Aceragen Inc
ACGN
$3.38M 0.48%
+16,561
New +$3.95M
MDCO
25
DELISTED
Medicines Co
MDCO
$2.71M 0.38%
+79,899
New +$2.83M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, RA Capital Management held 36 positions worth $706M, down 27% from $969M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

RA Capital Management withdrew a net $179M in Q4 2016, closing 9 positions and reducing 10 holdings. Its most notable exit was Sio Gene Therapies Inc. Common Stock, an estimated $70M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Ra Pharmaceuticals, Inc. Common Stock worth $20.5M.

  • RA Capital Management's largest Q4 2016 buy was Ra Pharmaceuticals, Inc. Common Stock: 1,351,808 shares worth $20.5M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q4 2016, an estimated $34.5M increase.
  • RA Capital Management's biggest Q4 2016 reduction was TG Therapeutics, cutting an estimated $21.3M.
  • RA Capital Management fully exited Sio Gene Therapies Inc. Common Stock in Q4 2016, selling an estimated $70M.
  • RA Capital Management's ten largest holdings make up 84% of its $706M portfolio in Q4 2016.
  • RA Capital Management opened 6 new positions and closed 9 in Q4 2016.
  • RA Capital Management's portfolio value fell 27% quarter-over-quarter to $706M.

Based on RA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.